确定阿克拉鲁比在儿科恶性瘤中的临床前安全性
Darleen S Tu1, Aaron K Olson2,3, Kimberly S Waggie4
1Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Pediatric blood & cancer
|November 27, 2025
概括
阿克拉鲁比 (Acla) 在儿童癌症中表现出强大的抗瘤作用,与多克索鲁比 (Doxo) 相比,毒性降低. 这种破坏色素的药物提供了一个更安全的替代品,即使在先前进行了环素治疗之后.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 人环素对于儿科癌症治疗至关重要,但会导致剂量限制性毒性,如心脏毒性和二次癌症.
- 阿克拉鲁比 (Acla) 是一种人类循环素衍生物,其向的是染色质损伤,可能减少长期副作用.
- 这项研究探讨了Acla的疗效和安全性,特别是在涉及先前暴露于 antracycline的场景中.
研究的目的:
- 在儿童癌症模型中评估Aclarubicin (Acla) 的抗瘤疗效.
- 评估Acla的安全性,重点是基因毒性压力和器官毒性.
- 为了比较Acla与多克索鲁比辛 (Doxo) 的效果,在人类循环素再治疗模型中.
主要方法:
- 在体外测试Acla对儿科癌症细胞系的试验.
- 在体内小鼠模型模拟Doxorubicin (Doxo) 暴露后的Anthracycline再治疗.
- 瘤生长,基因毒性,存活率和器官损伤的评估.
主要成果:
- 在儿童癌症模型中,阿克拉鲁比 (Acla) 显示出与多克索鲁比 (Doxo) 相当的抗瘤活性.
- 与Doxo不同的是,Acla治疗没有诱导显著的基因毒性压力.
- 在体内研究表明,在暴露于Doxo后,Acla没有显示累积心脏毒性或器官损伤,而第二次Doxo疗程导致显著的毒性死亡率.
结论:
- 阿克拉鲁比 (Acla) 是治疗儿科癌症的有希望的替代品,因为它具有强大的疗效和改善的安全性,即使在以前接受过治疗的患者中也是如此.
- 像Acla这样的染色体破坏性人环素需要进一步研究它们消除癌细胞的能力,而不会引起基因毒性压力.
- 临床前模型需要改进,以准确预测儿科和青少年群体的急性和慢性环素毒性.
更多相关视频
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
543
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.7K
相关概念视频
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
196
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
196
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
232
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232
01:28Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
179
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
247
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
247
01:29Drug Dosing: Infants and Children
235
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
235